UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2021

Commission File Number: 001-39152

FSD PHARMA INC.
(Translation of registrant's name into English)

First Canadian Place, 100 King Street West, Suite 3400
Toronto, ON M5X 1A4, Canada
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [  ]      Form 40-F [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to this Form 6-K are hereby filed and incorporated by reference into the registrant's Registration Statements on Form F-10 (Commission File Nos. 333-236780 and 333-254995).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FSD Pharma Inc.
	(Registrant)
Date: May 7, 2021	By: /s/ Raza Bokhari
	Name: Raza Bokhari
	Title: Executive Chairman & Chief Executive Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Condensed consolidated interim financial statements for the three months ended March 31, 2021 and 2020
99.2	Management's discussion and analysis of financial condition and results of operations for the three months ended March 31, 2021 and 2020